ALNYLAM PHARMACEUTICALS INC (ALNY)
US02043Q1076 - Common Stock
Notable Friday Option Activity: ILMN, QLYS, ALNY
Alnylam reports positive Phase 2 data for hypertension drug (NASDAQ:ALNY)
Alnylam Pharmaceuticals announces positive Phase 2 study results for zilebesiran, a potential treatment for hypertension and high cardiovascular risk.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...
ALNY May 2024 Options Begin Trading
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Commit To Buy Alnylam Pharmaceuticals At $120, Earn 18% Annualized Using Options
Alnylam Pharmaceuticals Larger Than S&P 500 Component Targa Resources
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
The company can begin a pivotal study of its treatment for cardiomyopathy.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...
Alnylam stock downgraded at Oppenheimer (NASDAQ:ALNY)
Oppenheimer downgrades Alnylam Pharmaceuticals as it prepares to release data from its HELIOS-B study for amyloidosis therapyvutrisiran early next year. Read more here.
Notable Monday Option Activity: ALNY, SPOT, DDOG
Arbutus stock lower after FDA snub for Alnylam drug
The FDA rejection of Alnylam's amyloidosis therapy impacts Arbutus Biopharma, which has a licensing deal with the company for the product. Read more here.
Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug
Shares skidded to their lowest point since September on the FDA's rejection.
2 Growth Stocks That Could Rocket Higher Before the End of 2023
Potential approvals of new medicines expected soon could push these stocks through the roof.
Ionis, AbbVie, Alnylam draw bullish views at Raymond James (NYSE:ABBV)
Raymond James initiated coverage on Ionis Pharmaceuticals, AbbVie, and Alnylam Pharmaceuticals with buy-equivalent ratings. Read more here.
Noteworthy Friday Option Activity: BW, ALNY, BMBL
Alnylam stock falls after FDA panel questions drug's effectiveness (ALNY)
Alnylam (ALNY) stock was down 8% Thursday, the day after an FDA advisory panel questioned the effectiveness of its drug patisiran in treating ATTR-CM. Read more here.